AML is swarming
with challenges
Impact of disease
• Acute myeloid leukemia (AML) is the most common type of leukemia in
adults, accounting for approximately 25% of leukemia diagnoses, with an
estimated 19,950 new cases in the United States this year1,2
• The 5-year survival rate in patients with AML is about 26%1
• An estimated 10,430 patients will die from AML this year1
AML evolves rapidly because of its polyclonal and
heterogeneous features, contributing to the clinical
challenges of this disease3
• As indicators of prognosis, cytogenetic and molecular mutation
testing are recommended by the National Comprehensive Cancer
Network® (NCCN®) at diagnosis4
• Evaluation of molecular mutations may be important for risk
assessment and prognosis to help guide treatment decisions4